Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.65 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16351544 | 0.91 | SLC5A2 (0.73) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18891722 | 0.91 | SLC5A2 (0.67) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18891569 | 0.91 | SLC5A2 (0.73) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14793157 | 0.86 | SLC5A2 (0.74) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16351542 | 0.86 | SLC5A2 (0.74) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16361652 | 0.85 | SLC5A2 (0.68) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL28407124 | 0.82 | SLC5A2 (0.77) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17623721 | 0.81 | SLC5A2 (0.76) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL24849985 | 0.81 | SLC5A2 (0.73) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18891723 | 0.80 | SLC5A2 (0.41) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018249-B2 | SGLT inhibitors | PANACEA BIOTEC LIMITED (IN) | 2015-04-28 | — | — | US | disclosed |
| US-9018249-B2 | SGLT inhibitors | PANACEA BIOTEC LIMITED (IN) | 2015-04-28 | — | — | US | disclosed |
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2014-12-25 | — | — | US | disclosed |
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.